v3.19.3

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and equivalents	$ 68,448	$ 104,566
Accounts receivable, net	1,244	612
Inventory, net	4,683	4,390
Prepaid expenses and other current assets	2,850	2,239
Total current assets	77,225	111,807
Furniture and equipment, net	579	362
Operating lease asset	1,146	0
Total assets	78,950	112,169
Current liabilities
Accounts payable	1,859	781
Accrued expenses	10,920	11,935
Accrued interest	182	79
Due to related party	0	35
Current portion of operating lease liability	338	0
Current portion of long-term debt	1,913	6,667
Total current liabilities	15,212	19,497
Deferred revenue	453	2,373
Long-term operating lease liability	1,123	0
Long-term debt	28,924	13,941
Total liabilities	45,712	35,811
Commitments and contingencies
Stockholders’ equity
Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 28,821,405 and 28,204,098 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	29	28
Additional paid-in capital	217,364	205,757
Accumulated deficit	(184,155)	(129,427)
Total stockholders’ equity	33,238	76,358
Total liabilities and stockholders’ equity	$ 78,950	$ 112,169

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Dova Pharmaceuticals Inc. 10-Q